Oppenheimer Asset Management Inc. Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Oppenheimer Asset Management Inc. boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 17.3% in the third quarter, HoldingsChannel.com reports. The fund owned 13,360 shares of the medical research company’s stock after purchasing an additional 1,974 shares during the period. Oppenheimer Asset Management Inc.’s holdings in IQVIA were worth $3,166,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Cumberland Partners Ltd boosted its holdings in IQVIA by 4.1% during the 3rd quarter. Cumberland Partners Ltd now owns 1,660 shares of the medical research company’s stock valued at $393,000 after acquiring an additional 65 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in IQVIA by 3.9% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,023,264 shares of the medical research company’s stock valued at $242,483,000 after acquiring an additional 38,307 shares during the period. GSA Capital Partners LLP purchased a new position in IQVIA during the 3rd quarter valued at about $230,000. Apollon Wealth Management LLC boosted its holdings in IQVIA by 9.6% during the 3rd quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company’s stock valued at $1,155,000 after acquiring an additional 427 shares during the period. Finally, Keystone Financial Services acquired a new stake in IQVIA in the 3rd quarter valued at about $238,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IQV. TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Finally, Morgan Stanley reduced their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Trading Down 5.1 %

IQV opened at $192.63 on Friday. The firm has a market cap of $34.96 billion, a price-to-earnings ratio of 25.28, a price-to-earnings-growth ratio of 2.17 and a beta of 1.51. IQVIA Holdings Inc. has a 52 week low of $189.63 and a 52 week high of $261.73. The business’s 50 day moving average is $227.96 and its two-hundred day moving average is $228.59. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.